CareDx, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
CDNA$80.77-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Operating activities: | |||
| Net (loss) income | $(21,354) | $52,549 | $(190,284) |
| Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: | |||
| Stock-based compensation | 34,864 | 66,406 | 49,086 |
| Asset impairments and write-downs | — | — | 1,000 |
| Impairment of intangible asset and associated construction in progress | 2,258 | — | — |
| Depreciation and amortization | 15,018 | 14,194 | 14,386 |
| Amortization of right-of-use assets | 5,398 | 5,563 | 5,438 |
| Realized gain on sale of long-term marketable equity securities, net | — | — | (284) |
| Loss on disposal of asset | 48 | 91 | 44 |
| Gain on settlement of obligation and recovery of written-off investment | — | — | (2,109) |
| Revaluation of common stock warrant liability to estimated fair value | — | — | (10) |
| Revaluation of contingent consideration to estimated fair value | 703 | 931 | 2,677 |
| Amortization of premium and accretion of discount on marketable securities, net | 1,273 | 621 | (4,927) |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 22,521 | (13,741) | 16,016 |
| Inventory | (4,959) | (1,018) | 54 |
| Prepaid and other assets | (4,413) | 606 | 1,767 |
| Accounts payable | 808 | (5,110) | 2,904 |
| Accrued compensation | (845) | 18,667 | 2,655 |
| Accrued and other liabilities | (3,308) | (95,661) | 89,608 |
| Accrued royalties | — | — | (1,557) |
| Operating lease liabilities, net | (5,997) | (5,863) | (5,418) |
| Deferred taxes | 17 | (187) | 566 |
| Net cash provided by (used in) operating activities | 42,032 | 38,048 | (18,388) |
| Investing activities: | |||
| Maturities of marketable securities | 154,671 | 166,921 | 256,038 |
| Purchases of marketable securities | (145,925) | (160,286) | (201,165) |
| Purchase of corporate equity securities | — | (634) | (965) |
| Sale of corporate equity securities | — | — | 2,460 |
| Additions of capital expenditures | (5,913) | (6,484) | (8,344) |
| Acquisition of intangible assets | (675) | — | (896) |
| Acquisition of business, net of cash acquired | — | — | (6,682) |
| Net cash provided by (used in) investing activities | 2,158 | (483) | 40,446 |
| Financing activities: | |||
| Payment of contingent consideration | (1,500) | (5,325) | (625) |
| Repurchase and retirement of common stock | (87,768) | (522) | (27,541) |
| Proceeds from exercise of warrants | — | — | 4 |
| Proceeds from exercise of stock options | 5,723 | 8,936 | 120 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,272 | 1,397 | 1,495 |
| Taxes paid related to net share settlement of restricted stock units | (12,121) | (10,092) | (3,059) |
| Net cash used in financing activities | (93,394) | (5,606) | (29,606) |
| Effect of exchange rate changes on cash and cash equivalents | (90) | 532 | (112) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (49,294) | 32,491 | (7,660) |
| Cash, cash equivalents, and restricted cash at beginning of period | 115,274 | 82,783 | 90,443 |
| Cash, cash equivalents, and restricted cash at end of period | $65,980 | $115,274 | $82,783 |
| Supplemental disclosures of cash information | |||
| Cash paid for income taxes | $284 | $317 | $738 |
| Supplemental disclosures of non-cash operating, investing and financing information | |||
| Shares issued in lieu of payment | $88 | $174 | $216 |
| Operating lease right-of-use assets | $3,368 | $195 | $607 |
| Purchases of capital expenditures in accounts payable and accrued liabilities | $3,209 | $633 | $647 |
| Employee stock purchase plan shares included in accrued compensation | $1,140 | $975 | $556 |
| Contingent consideration | $— | $— | $3,499 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.